Rottapharm of Italy, which at the start of July was planning an initial public offering (IPO) by month-end, is to be acquired by Sweden's Meda for SEK21.2bn (€2.275bn).
Meda in €2.3bn Rottapharm acquisition
Rottapharm of Italy, which at the start of July was planning an initial public offering (IPO) by month-end, is to be acquired by Sweden's Meda for SEK21.2bn (€2.275bn).
More from Deals
• By
The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
• By
The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.
• By
The German group is paying $3.9bn to get hold of the US firm and its two approved products.
More from Business
• By
Merck is investing $ 1bn in a Delaware facility to produce Keytruda and expand biologics manufacturing amid US tariff concerns.
• By
Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.